Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656239 | 0.86 | PTGER1 (0.47) | PPARAL3MBTL1CYP2C9PTGER1GRIN2B | |
| SCHEMBL2644395 | 0.84 | PPARA (0.48) | PPARAL3MBTL1CYP2C9PTGER1GRIN2B | |
| SCHEMBL2645197 | 0.81 | GSK3B (0.38) | GRIN2BSYKHDAC1 | |
| SCHEMBL25257191 | 0.80 | SYK (0.42) | L3MBTL1CYP2C9PTGER1SYKMEN1 | |
| SCHEMBL29007908 | 0.76 | TMEM97 (0.40) | GRIN2BHDAC1POLB | |
| SCHEMBL12579812 | 0.75 | GCK (0.46) | CYP2C9PTGER1GRIN2BMEN1NPC1 | |
| SCHEMBL6078486 | 0.75 | SMN1; SMN2 (0.41) | CYP2C9PTGER1GAAKMT2ALMNA | |
| SCHEMBL10515590 | 0.74 | PTGER1 (0.54) | PPARACYP2C9PTGER1GRIN2BCTSS | |
| SCHEMBL32681571 | 0.74 | SIRT6 (0.42) | GRIN2BMEN1NPC1RAB9AKMT2A | |
| SCHEMBL3509640 | 0.73 | P4HTM (0.51) | GRIN2BMEN1KMT2ALNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-11-11 | — | — | US | disclosed |
| WO-2009091014-A1 | PHENYL ACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | AADAC, PGC, PC | PPARA 16/4885L3MBTL1 4317/4885CYP2C9 1505/4885 |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | PC, PCK2, GCKR | PPARA 89/4885L3MBTL1 4654/4885CYP2C9 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.